ITO EN Oi Ocha Green Teas Coming Soon to Walmart
30.7.2019 15:15:00 EEST | Business Wire | Press release
ITO EN (North America) INC. the global leaders of green tea and innovators of healthy beverages today announced that their Oi Ocha ready-to-drink green tea brand, will soon be available in Walmart stores nationwide. Slated for placement in October 2019 with two unsweetened flavors- ITO EN’s premium Oi Ocha green tea, Japan’s top selling brand and Jasmine Green Tea, a popular green tea infused with jasmine flowers. The award-winning teas are celebrated for their naturally smooth taste and clean finish, brewed with ITO EN’s proprietary brewing method using whole tea leaves without artificial additives, flavors or colors, and powders or concentrates. The authentic and refreshing teas are Non-GMO certified with natural catechin tea antioxidants, natural Vitamin C (Ascorbic Acid) and zero calories. Each packaged in a convenient on the go 16.9 fl. oz recyclable PET bottle.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190730005425/en/
ITO EN Oi Ocha and Jasmine Green Tea. (Photo: Business Wire)
“With a growing number of consumers looking for authentic and healthy beverages, we could not be more excited to expand Ito En’s tea products into Walmart stores nationwide,” says Jim Hoagland, COO at ITO EN (North America) INC. “With Walmart responding to the growing consumer interest for high-quality, authentic and better-for-you products, we are confident that our traditional unsweetened green teas are a great fit for Walmart and their customers.”
The Oi Ocha brand has been growing exponentially in the U.S. market as consumer demand for authentic and healthier beverages continues to grow across the specialty, mainstream markets, and food service channels. The partnership with Walmart not only broadens ITO EN’s brand awareness and distribution but will also give accessibility to a better-for-you beverage to the everyday consumer. With green tea gaining popularity for its health benefits while consumers seek sugar free beverages, unsweetened Oi Ocha teas are ideal to integrate into daily life.
ITO EN is specifically known for its commitment to tea expertise and sustainable practices that are reflected across all of its award-winning brands. With over 50 years of tea expertise, the company is dedicated to authenticity, preserving its culture while creating global innovation for the tea and beverage industry. ITO EN is proud to have ranked #18 in FORTUNE's top 50 Companies that have made an important social or environmental impact through its profit-making strategy and operations. The company was also awarded a sustainability award for its used tea leaf recycling program, creating innovative products from a eco-friendly synthetic resin made from used tea leaves. For more information on ITO EN and its products, please visit www.itoen.com.
About ITO EN:
ITO EN (North America) INC., a subsidiary of ITO EN (Japan) LTD., is an innovative beverage industry leader dedicated to creating authentic products that embody the company’s five principles of Natural, Healthy, Safe, Well-designed and Delicious. With over 50 years of tea expertise in Japan, ITO EN is dedicated to authenticity, preserving its culture while creating global innovation, making it known as Japan’s #1 green tea purveyor with award-winning brands, including TEAS’ TEA Organic®, Oi Ocha®, ITO EN Shots® and matcha LOVE®. ITO EN’s strong commitment to social and environmental impact manifests in its partnerships with regional farmers and governments to stimulate local economies, development of sustainable procurement practices and nurture a new generation of tea farming. To learn more about ITO EN, visit www.itoen.com. ‘Like’ us on Facebook or follow us on Twitter and Instagram.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190730005425/en/
Contact information
Rona Tison
ITO EN (North America) INC.
rtison@itoen.com
T. 707-327-6413
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom